vzphotos/iStock Editorial via Getty Images The European Commission has given AbbVie (NYSE:ABBV) and Genmab (GMAB)
ModernLife Shares of Aldeyra Therapeutics (NASDAQ:ALDX) surged ~26% on Thursday after the company said its
Luis Alvarez Wells Fargo analyst Christopher P. Harvey put together a list of his top
Michael Vi/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) has completed its ~$8.7B ($45 per share)
vzphotos/iStock Editorial via Getty Images Cerevel Therapeutics (NASDAQ:CERE) edged higher by 0.5% in premarket trading
Summary: On July 25, AbbVie released its Q2 2024 financial results, which surprised me with
picha Although they receive the bulk of revenue from sales in the U.S. and report
Summary: AbbVie’s recent Q2 earnings release was robust, validating my initial bullish thesis, which has
Michael Vi/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) has discontinued a Phase 2 program for
vzphotos/iStock Editorial via Getty Images Update 9:45am: Updates shares, adds more AbbVie comments on timing